Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Neurosense Therapeutics Ltd. ( (NRSN) ) has issued an update.
On March 31, 2026, NeuroSense Therapeutics reported its financial results for the year ended December 31, 2025 and detailed a pivotal year in which PrimeC progressed from a successful Phase 2b ALS program into a late-stage clinical asset with FDA clearance for the Phase 3 PARAGON trial. The company highlighted 2025 Phase 2b PARADIGM data showing roughly 33% slowing of ALS disease progression over 18 months and reduced ALS-related complications, alongside completed commercial-scale manufacturing and active regulatory engagement, including with Health Canada.
In early 2026, NeuroSense announced statistically significant survival data from its Phase 2b study, including a 65% reduction in risk of death and more than a 14‑month median survival benefit, with the results published in JAMA Neurology, bolstering the clinical credibility of PrimeC. The company also reported biomarker signals in Alzheimer’s disease, expanded its intellectual property and scientific advisory base, and outlined near-term milestones such as additional biomarker readouts, a planned pre-NDS meeting in Canada in May 2026, and ongoing Phase 3 preparations, all against a backdrop of rising R&D and G&A expenses and a cash balance of about $0.2 million at year-end 2025, underscoring funding needs as it advances late-stage trials.
The most recent analyst rating on (NRSN) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Neurosense Therapeutics Ltd. stock, see the NRSN Stock Forecast page.
Spark’s Take on NRSN Stock
According to Spark, TipRanks’ AI Analyst, NRSN is a Neutral.
The score is primarily constrained by weak financial performance (no revenue, widening losses, and increasing cash burn), which elevates funding and dilution risk. Technical signals are mixed with a weak longer-term trend despite neutral momentum, and valuation is limited by negative earnings and no dividend support.
To see Spark’s full report on NRSN stock, click here.
More about Neurosense Therapeutics Ltd.
NeuroSense Therapeutics Ltd. is a late-stage clinical biotechnology company focused on developing treatments for severe neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and Alzheimer’s disease. Its lead drug candidate, PrimeC, is being advanced as a potentially disease-modifying therapy, supported by biomarker data and a defined regulatory and development pathway in major markets.
Average Trading Volume: 211,028
Technical Sentiment Signal: Sell
Current Market Cap: $21.71M
For detailed information about NRSN stock, go to TipRanks’ Stock Analysis page.